Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Ischemic HFrEF
NCT03791593Phase 2Completed
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evolocumab in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Germans Trias i Pujol Research Institute. Primary endpoint: Change in high-sensitivity troponin T levels at 1 year. Started Dec 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03791593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791593.